These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 28586335)

  • 1. Biology and evolution of poorly differentiated neuroendocrine tumors.
    Rickman DS; Beltran H; Demichelis F; Rubin MA
    Nat Med; 2017 Jun; 23(6):1-10. PubMed ID: 28586335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
    Quintanal-Villalonga Á; Chan JM; Yu HA; Pe'er D; Sawyers CL; Sen T; Rudin CM
    Nat Rev Clin Oncol; 2020 Jun; 17(6):360-371. PubMed ID: 32152485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation.
    Quintanal-Villalonga A; Kawasaki K; Redin E; Uddin F; Rakhade S; Durani V; Sabet A; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Kinyua D; Zhong H; Mello BP; Ciampricotti M; Bhanot UK; Linkov I; Qiu J; Patel RA; Morrissey C; Mehta S; Barnes J; Haffner MC; Socci ND; Koche RP; de Stanchina E; Molina-Pinelo S; Salehi S; Yu HA; Chan JM; Rudin CM
    Signal Transduct Target Ther; 2024 Jul; 9(1):189. PubMed ID: 39054323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.
    Shen P; Jing Y; Zhang R; Cai MC; Ma P; Chen H; Zhuang G
    Oncogene; 2018 May; 37(22):3039-3044. PubMed ID: 29535424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
    Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
    Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes.
    Lázaro S; Pérez-Crespo M; Lorz C; Bernardini A; Oteo M; Enguita AB; Romero E; Hernández P; Tomás L; Morcillo MÁ; Paramio JM; Santos M
    Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22300-22306. PubMed ID: 31611390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Taxotere in various solid tumors].
    Orel NF
    Vopr Onkol; 1998; 44(5):639-44. PubMed ID: 9925501
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
    Swarts DR; Ramaekers FC; Speel EJ
    Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic alterations in neuroendocrine cancers of the ovary.
    Yaghmour G; Prouet P; Wiedower E; Jamy OH; Feldman R; Chandler JC; Pandey M; Martin MG
    J Ovarian Res; 2016 Aug; 9(1):52. PubMed ID: 27566252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma.
    Ohmoto A; Sato Y; Asaka R; Fukuda N; Wang X; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takeuchi K; Mori S; Takahashi S
    Mod Pathol; 2021 Nov; 34(11):1979-1989. PubMed ID: 34247193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Alterations of Both MEN1/ATRX and TP53/RB1 in Pancreatic Neuroendocrine Neoplasms.
    Zhang MY; He D; Zhang S; Liu JY
    Pancreas; 2022 Jul; 51(6):e91-e93. PubMed ID: 36206476
    [No Abstract]   [Full Text] [Related]  

  • 12. Correlation of PSMA-Targeted
    Tosoian JJ; Gorin MA; Rowe SP; Andreas D; Szabo Z; Pienta KJ; Pomper MG; Lotan TL; Ross AE
    Clin Genitourin Cancer; 2017 Feb; 15(1):e65-e68. PubMed ID: 27751686
    [No Abstract]   [Full Text] [Related]  

  • 13. [Expression and co-expression of cellular oncogenes in the course of tumor progression in neuroendocrine lung tumors].
    Kogan EA; Shtabskiĭ AB; Sekamova SM; Sukhova NM; Mazurenko NN
    Arkh Patol; 1994; 56(2):16-21. PubMed ID: 8037585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis.
    Sampietro G; Tomasic G; Collini P; Biganzoli E; Boracchi P; Bidoli P; Pilotti S
    Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):49-56. PubMed ID: 10937049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.
    Li Z; Sun Y; Chen X; Squires J; Nowroozizadeh B; Liang C; Huang J
    Mol Cancer Res; 2015 Mar; 13(3):584-91. PubMed ID: 25512615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.
    Ku SY; Rosario S; Wang Y; Mu P; Seshadri M; Goodrich ZW; Goodrich MM; Labbé DP; Gomez EC; Wang J; Long HW; Xu B; Brown M; Loda M; Sawyers CL; Ellis L; Goodrich DW
    Science; 2017 Jan; 355(6320):78-83. PubMed ID: 28059767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
    Raj N; Reidy-Lagunes D
    Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
    Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
    BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.